title: [Effect of imatinib treatment of gastrointestinal stromal tumors].
abstract: BACKGROUND
  Advanced malignant gastrointestinal stromal tumours are practically resistant to further radio- or chemotherapy. These tumours are characterized by the presence of C-KIT (a transmembrane tyrosin kinase) mutation which can be specified by CD117 expression. Imatinib (2-fenilaminopirimidine) is a selective inhibitor of the mutated C-KIT.
  
  
  OBJECTIVE
  The purpose of our study was to determine the potential antitumour effect of imatinib in patients with gastrointestinal stroma tumour patients.
  
  
  METHODS
  An open, non-randomized trial was performed involving 38 patients each of which had received/metastatic disease associated with CD117 positivity. Consecutively daily doses of 400-600 mg imatinib was administered orally to the patients. The evaluation was carried out on 37 patients in a form of an interim analysis.
  
  
  RESULTS
  After a 3-18 months observation period 1 complete, 19 partial remissions and 10 static diseases could be registered (78%), in association of only grade 1-2 toxicity.
  
  
  CONCLUSIONS
  The imatinib treatment improved the quality of life of the patients with gastrointestinal stroma tumour and their life expectancy became considerably prolonged. Further follow-up of the patients as well as design of a prospective, randomized trial on a larger patient material is urgently needed.
authors.affiliation: Országos Onkológiai Intézet, B Belgyógyászati Osztály, Budapest. eckhardt@oncol.hu
authors.forename: Sándor
authors.initials: S
authors.lastname: Eckhardt
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Pápai
authors.forename: György
authors.initials: G
authors.lastname: Bodoky
authors.forename: József
authors.initials: J
authors.lastname: Horti
authors.forename: Karin
authors.initials: K
authors.lastname: Tamás
authors.forename: Tünde
authors.initials: T
authors.lastname: Nagy
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Orosz
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Sápi
authors.forename: Mária
authors.initials: M
authors.lastname: Gödény
authors.forename: Klára
authors.initials: K
authors.lastname: Jakab
authors.forename: Olga
authors.initials: O
authors.lastname: Esik
authors.forename: Lajos
authors.initials: L
authors.lastname: Trón
authors.forename: István
authors.initials: I
authors.lastname: Besznyák
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D000068877:Imatinib Mesylate; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D017154:Stromal Cells; D016019:Survival Analysis; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate